Quarterly report pursuant to Section 13 or 15(d)

Original AL001 License: (Details)

v3.21.2
Original AL001 License: (Details)
3 Months Ended
Jul. 31, 2021
USD ($)
A L 001 License [Member] | Pre Ind Meeting [Member]  
Product Liability Contingency [Line Items]  
Payment $ 50,000
Due Date  Completed September 2019
A L 001 License [Member] | Ind Application Filing [Member]  
Product Liability Contingency [Line Items]  
Payment $ 65,000
Due Date  6 months from the June 30, 2021 IND filing date
A L 001 License [Member] | Upon First Dosing Of Patient In Clinical Trial [Member]  
Product Liability Contingency [Line Items]  
Payment $ 190,000
Due Date  12 months from the June 30, 2021 IND filing date
A L 001 License [Member] | Upon Completion Of First Clinical Trial [Member]  
Product Liability Contingency [Line Items]  
Payment $ 500,000
Due Date  12 months from first patient dosing
A L 001 License [Member] | Upon First Patient Treated In Phase 3 Clinical Trial [Member]  
Product Liability Contingency [Line Items]  
Payment $ 1,250,000
Due Date  12 months from completion of the first Phase II clinical trial
A L 001 License [Member] | Upon Fda Approval [Member]  
Product Liability Contingency [Line Items]  
Payment $ 10,000,000
Due Date  8 years from the effective date of the agreement
A L 002 License [Member] | Pre Ind Meeting [Member]  
Product Liability Contingency [Line Items]  
Payment $ 50,000
Due Date  Upon IND application filing
A L 002 License [Member] | Ind Application Filing [Member]  
Product Liability Contingency [Line Items]  
Payment $ 50,000
Due Date  12 months from IND application filing date
A L 002 License [Member] | Upon First Dosing Of Patient In Clinical Trial [Member]  
Product Liability Contingency [Line Items]  
Payment $ 175,000
Due Date  12 months from first patient dosed in Phase I
A L 002 License [Member] | Upon Completion Of First Clinical Trial [Member]  
Product Liability Contingency [Line Items]  
Payment $ 500,000
Due Date  24 months from completion of first Phase I clinical trial
A L 002 License [Member] | Upon First Patient Treated In Phase 3 Clinical Trial [Member]  
Product Liability Contingency [Line Items]  
Payment $ 1,000,000
Due Date  12 months from completion of the first Phase II clinical trial
A L 002 License [Member] | Upon Fda Approval [Member]  
Product Liability Contingency [Line Items]  
Payment $ 10,000,000
Due Date  7 years from the effective date of the agreement
Additional A L 001 License [Member] | Pre Ind Meeting [Member]  
Product Liability Contingency [Line Items]  
Payment $ 30,000
Due Date  Completed September 2019
Additional A L 001 License [Member] | Ind Application Filing [Member]  
Product Liability Contingency [Line Items]  
Payment $ 50,000
Due Date  December 31, 2022
Additional A L 001 License [Member] | Upon First Dosing Of Patient In Clinical Trial [Member]  
Product Liability Contingency [Line Items]  
Payment $ 150,000
Due Date  12 months from IND filing date
Additional A L 001 License [Member] | Upon Completion Of First Clinical Trial [Member]  
Product Liability Contingency [Line Items]  
Payment $ 400,000
Due Date  12 months from first patient dosing
Additional A L 001 License [Member] | Upon First Patient Treated In Phase 3 Clinical Trial [Member]  
Product Liability Contingency [Line Items]  
Payment $ 1,000,000
Due Date  36 months from completion of the first Phase II clinical trial
Additional A L 001 License [Member] | Upon Fda Approval [Member]  
Product Liability Contingency [Line Items]  
Payment $ 8,000,000
Due Date  8 years from the effective date of the agreement